Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 19/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 7/20 | 0.52 |
| ▸ | NR4A1 | P22736 | 2/20 | 0.50 |
| ▸ | JMJD7 | P0C870 | 1/20 | 0.50 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.50 |
| ▸ | FABP4 | P15090 | 1/20 | 0.47 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6756236 | 0.90 | DHODH (0.58) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL6859682 | 0.83 | DHODH (0.64) | DHODHNR4A2 | |
| SCHEMBL6754127 | 0.82 | DHODH (0.59) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL7041288 | 0.80 | DHODH (0.60) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL17415621 | 0.79 | DHODH (0.54) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL6754645 | 0.77 | DHODH (0.65) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL6754882 | 0.77 | DHODH (0.62) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL6754115 | 0.77 | DHODH (0.60) | DHODHNR4A2FABP4FABP5 | |
| SCHEMBL6815996 | 0.77 | DHODH (0.54) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL248162 | 0.76 | DHODH (0.62) | DHODHNR4A2NR4A1JMJD7NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003006425-A9 | NOVEL COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2004-02-26 | — | — | WO | disclosed |